Looking Into Leap Therapeutics's Return On Capital Employed

By: via Benzinga
Benzinga Pro data, Leap Therapeutics (NASDAQ:LPTX) reported Q2 sales of $375.00 thousand. Earnings fell to a loss of $9.63 million, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.